• Molecular NameTesaglitazar
  • SynonymNA
  • Weight408.471
  • Drugbank_IDN/A
  • ACS_NO251565-85-2
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.22
  • pkaN/A
  • LogD (pH=7, predicted)-0.06
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.87
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.09
  • No.of HBond Donors1
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds11
  • TPSA107.51
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA peroxisome proliferator-activated receptor agonist with affinity to PPARĪ± and PPARĪ³, proposed for type 2 diabetes. The drug had completed several phase III clinical trials, however in May, 2006 AstraZeneca announced that it had discontinued further development.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability100.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A